Ergoteles’s AEON Biopharma AEON Stock Holding History

Ergoteles’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-363	Closed	-$262K	–	1201
2022 Q4	$262K	Buy	+363	New	+$260K	0.01%	963

Other funds holding AEON

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

Ergoteles's AEON Position: Q1 2023 in Review

Ergoteles sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 363 shares — an estimated $262K sold.

Ergoteles first reported a position in AEON in Q4 2022 and held it in 1 quarter. The position peaked at $262K in Q4 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

Ergoteles reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 363 AEON Biopharma shares in Q1 2023, an estimated $262K.
Ergoteles first reported a position in AEON Biopharma in Q4 2022 and held it in 1 quarter.
Ergoteles's AEON Biopharma position peaked at $262K in Q4 2022.
21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.